Closing Thoughts on GU Cancer Updates from ESMO 2023

News
Video

Following their program on data updates in GU cancer from ESMO 2023, Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, share key takeaways from SunRISe-1, EV-302, and PSMAfore.

Current Time 0:00
Duration 1:05
Loaded: 0%
Stream Type LIVE
Remaining Time 1:05
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Recent Videos
    EPIC-A Trial Insights on Cemiplimab and Chemotherapy in Penile Carcinoma
    EPIC-A Trial Insights on Cemiplimab and Chemotherapy in Penile Carcinoma
    Basu Discusses Tumor-Informed MRD Assays and Clinical Decision-Making
    Basu Discusses Tumor-Informed MRD Assays and Clinical Decision-Making
    Behind the Design of the PEACE-1 Trial in mCSPC
    Behind the Design of the PEACE-1 Trial in mCSPC
    Reviewing the Options for Bladder Cancer in Different Settings
    Reviewing the Options for Bladder Cancer in Different Settings
    Epigenomic Platform Enhances Access to PSMA-Based Prostate Cancer Therapies
    Epigenomic Platform Enhances Access to PSMA-Based Prostate Cancer Therapies
    Ga 68 PSMA-11 in BgRT: Targeting Bony Metastases in Prostate Cancer
    Ga 68 PSMA-11 in BgRT: Targeting Bony Metastases in Prostate Cancer
    Mapping ctDNA Shedding Differences in GU Cancers With MRD Testing
    Mapping ctDNA Shedding Differences in GU Cancers With MRD Testing
    Liquid Biopsies Enhance PSMA-Directed Therapies in GU Cancers
    Liquid Biopsies Enhance PSMA-Directed Therapies in GU Cancers
    Opinions on Treatment Split for Prominent Questions in Bladder Cancer
    Opinions on Treatment Split for Prominent Questions in Bladder Cancer
    AI Tools for Accurate Cancer Diagnosis and Tailored Treatment
    AI Tools for Accurate Cancer Diagnosis and Tailored Treatment
    Related Content
    Updated Efficacy Shows Nivolumab Boosts Survival in High-Risk MIBC

    Updated Efficacy Shows Nivolumab Boosts Survival in High-Risk MIBC

    Targeted Oncology Staff
    March 19th 2025
    Article

    During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer.

    Read More

    Transforming Prostate Cancer Care Through Personalized Medicine

    Transforming Prostate Cancer Care Through Personalized Medicine

    Jordyn Sava;Adam Weiner, MD
    July 1st 2024
    Podcast

    Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

    Listen

    Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision

    Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision

    Jordyn Sava
    March 13th 2025
    Article

    177Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic castration-resistant prostate cancer.

    Read More

    Dizman’s Global Pursuit to Cancer Research and Understanding

    Dizman’s Global Pursuit to Cancer Research and Understanding

    Jordyn Sava;Nazli Dizman, MD
    April 1st 2024
    Podcast

    In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

    Listen

    Bridging the Gap: Global Disparities in RCC Clinical Trial Access

    Bridging the Gap: Global Disparities in RCC Clinical Trial Access

    Jordyn Sava
    March 1st 2025
    Article

    In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical trials.

    Read More

    FDA Grants Priority Review to TLX250-CDx in Kidney Cancer

    FDA Grants Priority Review to TLX250-CDx in Kidney Cancer

    Jordyn Sava
    February 28th 2025
    Article

    The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, 2025.

    Read More